A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Advanced Dry AMD

Trial Profile

A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Advanced Dry AMD

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs MA09 retinal pigment epithelial cell replacement therapy-Advanced Cell Technology (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Adverse reactions
  • Acronyms Dry AMD
  • Sponsors Astellas Institute for Regenerative Medicine; Ocata Therapeutics
  • Most Recent Events

    • 03 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 21 Oct 2015 Planned End Date changed from 1 Sep 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov record.
    • 21 Oct 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Aug 2014, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top